News

The Phase I trial is a randomized, placebo-controlled single-dose, dose-escalating study to evaluate the safety and pharmacokinetics of ACE-031. This clinical trial is the first-in-human study in the

Additionally, following key court rulings in favor of Celebrex, claims regarding Celebrex, a pain treatment, will also be resolved as part of the settlement. The announcement follows favorable

Accordingly, Ranbaxy has become a subsidiary of Daiichi Sankyo. Ranbaxy has now received through the preferential issue of equity shares and warrants an amount of $736 million from

The Central Designer technology provides one central and independent environment for building studies, where all teams work within a centralized system and one that allows for reuse of

These include the Eagan-based braemar division, manufacturer of cardiac monitoring systems as well as tissue management and fluid extraction equipment; the Chicago-based agility division, a clinical research organization

The trial was fully enrolled in 2007 with 626 patients and compared Gvax immunotherapy to Taxotere (docetaxel) chemotherapy plus prednisone. The company terminated the trial based on the

The collaboration provides the Radiation Therapy Oncology Group (RTOG) access to US Oncology’s significant patient population, making radiation therapy trials more accessible to cancer patients in the community

Since the acquisition, Exiqon has been integrating Oncotech and Exiqon to form ‘one company’ with multiple business divisions. Oncotech represents Exiqon’s diagnostics division and as part of this

The Aaron Klug Building is a 92,000sqft facility containing laboratories. The facility provides MedImmune with capacity to significantly increase the number of candidate drugs that it can develop